Free Trial

UCB (OTCMKTS:UCBJF) Reaches New 1-Year High - Here's What Happened

UCB logo with Medical background

Key Points

  • UCB SA shares reached a new 52-week high of $269.59, a significant increase from its previous close of $238.49, with a volume of 327 shares traded.
  • Wall Street analysts maintain a consensus rating of "Buy" for UCB, with Morgan Stanley reiterating an "overweight" rating in their recent report.
  • The company specializes in developing biopharmaceutical solutions for neurology and immunology diseases, with key products including Cimzia and Vimpat.
  • Five stocks to consider instead of UCB.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as $269.59 and last traded at $269.59, with a volume of 327 shares traded. The stock had previously closed at $238.49.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley reiterated an "overweight" rating on shares of UCB in a report on Monday, September 8th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, UCB has a consensus rating of "Buy".

Read Our Latest Research Report on UCB

UCB Trading Up 11.3%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm's 50-day simple moving average is $231.36 and its 200-day simple moving average is $196.67.

UCB Company Profile

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in UCB Right Now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.